BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35490242)

  • 1. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
    Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
    J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigene
    Bortolotti S; Angelucci S; Montemurro L; Bartolucci D; Raieli S; Lampis S; Amadesi C; Scardovi A; Nieddu G; Cerisoli L; Paganelli F; Chiarini F; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765949
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Maeshima R; Moulding D; Stoker AW; Hart SL
    Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
    Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
    Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
    Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
    Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
    Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma.
    Guan J; Li M; Wang Y; Zhang Y; Que Y; Lu S; Wang J; Zhu J; Huang J; Zhen Z; Sun F; Song M; Zhang Y
    Cell Death Dis; 2024 Feb; 15(2):124. PubMed ID: 38336749
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Raieli S; Di Renzo D; Lampis S; Amadesi C; Montemurro L; Pession A; Hrelia P; Fischer M; Tonelli R
    Front Oncol; 2021; 11():625207. PubMed ID: 33718189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
    Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
    Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A MYCN-independent mechanism mediating secretome reprogramming and metastasis in
    Zhang HF; Delaidelli A; Javed S; Turgu B; Morrison T; Hughes CS; Yang X; Pachva M; Lizardo MM; Singh G; Hoffmann J; Huang YZ; Patel K; Shraim R; Kung SHY; Morin GB; Aparicio S; Martinez D; Maris JM; Bosse KR; Williams KC; Sorensen PH
    Sci Adv; 2023 Aug; 9(34):eadg6693. PubMed ID: 37611092
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells.
    Wang J; Gu S; Huang J; Chen S; Zhang Z; Xu M
    BMC Cancer; 2014 Oct; 14():768. PubMed ID: 25323222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
    Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
    Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
    J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide.
    Reynolds CP; Wang Y; Melton LJ; Einhorn PA; Slamon DJ; Maurer BJ
    Med Pediatr Oncol; 2000 Dec; 35(6):597-602. PubMed ID: 11107126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
    Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z
    Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.